Abstract
The currently available type 1 cysteinyl leukotriene receptor (CysLT1R) antagonists have proven benefits for the treatment of asthma and allergic rhinitis. The type 2 cysteinyl leukotriene receptor (CysLT2R) mediates complex, cell type- or stimulus-specific functions that may either protect from or promote Type 2 immunity in allergic inflammation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
